Current clinical application of lutetium‑177 in solid tumors (Review)

Niu,Tingting; Fan,Mi; Lin,Binwei; Gao,Feng; Tan,Bangxian; Du,Xiaobo

doi:10.3892/etm.2024.12514

Current clinical application of lutetium‑177 in solid tumors (Review)

Authors:
- Tingting Niu
- Mi Fan
- Binwei Lin
- Feng Gao
- Bangxian Tan
- Xiaobo Du
View Affiliations

Affiliations: Department of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
Published online on: March 26, 2024 https://doi.org/10.3892/etm.2024.12514
Article Number: 225
Copyright: © Niu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radionuclide‑based therapy represents a novel treatment regimen for tumors. Among these therapies, lutetium‑177 (¹⁷⁷Lu) has gained significant attention due to its stability and safety, as well as its ability to emit both γ and β rays, allowing for both imaging with single photon emission computed tomography and tumor treatment. As a result, ¹⁷⁷Lu can be used for both diagnosis and treatment for diseases such as prostatic and gastric cancer. Therefore, based on the available data, the present review provides a brief overview of the clinical applications of ¹⁷⁷Lu‑targeted radionuclide therapy in metastatic prostate cancer, neuroendocrine tumors and other types of solid tumors, and highlights the current therapeutic effect, reduction in damage to normal tissues and future research directions, including the development of new nuclides and the application of more nuclides in different tumors. In the future, such treatments could be used in more tumors.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Al-Toubah T, Strosberg J, Hallanger-Johnson J and El-Haddad G: Targeted radionuclide therapy in endocrine-related cancers: Advances in the last decade. Front Endocrinol (Lausanne). 14(1187870)2023.PubMed/NCBI View Article : Google Scholar
3	Salih S, Alkatheeri A, Alomaim W and Elliyanti A: Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. Molecules. 27(5231)2022.PubMed/NCBI View Article : Google Scholar
4	Park UJ, Lee JS, Choi KH, Nam SS and Yu KH: Lu-177 preparation for radiotherapy application. Appl Radiat Isot. 115:8–12. 2016.PubMed/NCBI View Article : Google Scholar
5	Zakaly HMH, Mostafa MYA, Deryabina D and Zhukovsky M: Comparative studies on the potential use of ¹⁷⁷Lu-based radiopharmaceuticals for the palliative therapy of bone metastases. Int J Radiat Biol. 96:779–789. 2020.PubMed/NCBI View Article : Google Scholar
6	Dash A, Pillai MR and Knapp FF Jr: Production of (177)Lu for targeted radionuclide therapy: Available options. Nucl Med Mol Imaging. 49:85–107. 2015.PubMed/NCBI View Article : Google Scholar
7	Tan HY, Yeong CH, Wong YH, McKenzie M, Kasbollah A, Shah MNM and Perkins AC: Neutron-activated theranostic radionuclides for nuclear medicine. Nucl Med Biol. 90-91:55–68. 2020.PubMed/NCBI View Article : Google Scholar
8	Cao J, Chen Y, Hu M and Zhang W: ¹⁷⁷Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: Limitations and improvements. Ann Nucl Med. 35:861–870. 2021.PubMed/NCBI View Article : Google Scholar
9	Boegemann M, Schrader AJ and Rahbar K: ¹⁷⁷Lu-PSMA therapy: Current evidence for use in the treatment of patients with metastatic prostate cancer. Urologe A. 56:1440–1444. 2017.PubMed/NCBI View Article : Google Scholar : (In German).
10	Ghosh A and Heston WD: Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 91:528–539. 2004.PubMed/NCBI View Article : Google Scholar
11	Fendler WP, Rahbar K, Herrmann K, Kratochwil C and Eiber M: 177Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med. 58:1196–1200. 2017.PubMed/NCBI View Article : Google Scholar
12	Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Gorin MA, Solnes LB and Rowe SP: ¹⁷⁷ Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate. 82:826–835. 2022.PubMed/NCBI View Article : Google Scholar
13	Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, et al: 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 56:1169–1176. 2015.PubMed/NCBI View Article : Google Scholar
14	Barna S, Haug AR, Hartenbach M, Rasul S, Grubmüller B, Kramer G and Blaickner M: Dose calculations and dose-effect relationships in 177Lu-PSMA I&T radionuclide therapy for metastatic castration-resistant prostate cancer. Clin Nucl Med. 45:661–667. 2020.PubMed/NCBI View Article : Google Scholar
15	Hartrampf PE, Weinzierl FX, Serfling SE, Pomper MG, Rowe SP, Higuchi T, Seitz AK, Kübler H, Buck AK and Werner RA: Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T. Cancers (Basel). 14(647)2022.PubMed/NCBI View Article : Google Scholar
16	Bu T, Zhang L, Yu F, Yao X, Wu W, Zhang P, Shi L, Zang S, Meng Q, Ni Y, et al: 177Lu-PSMA-I&T radioligand therapy for treating metastatic castration-resistant prostate cancer: A single-centre study in East Asians. Front Oncol. 12(835956)2022.PubMed/NCBI View Article : Google Scholar
17	Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, et al: Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 15(17588359231156392)2023.PubMed/NCBI View Article : Google Scholar
18	Karimzadeh A, Heck M, Tauber R, Knorr K, Haller B, D'Alessandria C, Weber WA, Eiber M and Rauscher I: ¹⁷⁷Lu-PSMA-I&T for treatment of metastatic castration-resistant prostate cancer: Prognostic value of scintigraphic and clinical biomarkers. J Nucl Med. 64:402–409. 2023.PubMed/NCBI View Article : Google Scholar
19	Golan S, Frumer M, Zohar Y, Rosenbaum E, Yakimov M, Kedar D, Margel D, Baniel J, Steinmetz AP, Groshar D, et al: Neoadjuvant ¹⁷⁷Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: A single-arm phase 1 trial. Eur Urol Oncol. 6:151–159. 2023.PubMed/NCBI View Article : Google Scholar
20	Stasiuk GJ and Long NJ: The ubiquitous DOTA and its derivatives: The impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem Commun (Camb). 49:2732–2746. 2013.PubMed/NCBI View Article : Google Scholar
21	Keam SJ: Lutetium Lu 177 vipivotide tetraxetan: First approval. Mol Diagn Ther. 26:467–475. 2022.PubMed/NCBI View Article : Google Scholar
22	Liu X, Fang GC, Lu H, Shi ZD, Chen ZS and Han CH: Lutetium Lu 177 vipivotide tetraxetan for prostate cancer. Drugs Today (Barc). 59:37–49. 2023.PubMed/NCBI View Article : Google Scholar
23	Kim YJ and Kim YI: Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: A meta-analysis. Clin Nucl Med. 43:728–734. 2018.PubMed/NCBI View Article : Google Scholar
24	Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, et al: Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of ¹⁷⁷Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 61:857–865. 2020.PubMed/NCBI View Article : Google Scholar
25	Hofman MS, Violet J, Hicks RJ and Sandhu S: [¹⁷⁷Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer-Author's reply. Lancet Oncol. 19(e373)2018.PubMed/NCBI View Article : Google Scholar
26	Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 385:1091–1103. 2021.PubMed/NCBI View Article : Google Scholar
27	Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
28	Hartrampf PE, Weinzierl FX, Buck AK, Rowe SP, Higuchi T, Seitz AK, Kübler H, Schirbel A, Essler M, Bundschuh RA and Werner RA: Matched-pair analysis of [¹⁷⁷Lu]Lu-PSMA I&T and [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 49:3269–3276. 2022.PubMed/NCBI View Article : Google Scholar
29	Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D and Baum RP: Prostate-specific membrane antigen radioligand therapy using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: Comparison of safety, biodistribution, and dosimetry. J Nucl Med. 63:1199–1207. 2022.PubMed/NCBI View Article : Google Scholar
30	Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, et al: Health-related quality of life and pain outcomes with [¹⁷⁷Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24:597–610. 2023.PubMed/NCBI View Article : Google Scholar
31	Niaz MO, Sun M, Ramirez-Fort MK and Niaz MJ: Review of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody j591 for the treatment of metastatic castration-resistant prostate cancer. Cureus. 12(e7107)2020.PubMed/NCBI View Article : Google Scholar
32	Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R and Bander NH: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58:4055–4060. 1998.PubMed/NCBI
33	Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, et al: Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 38:848.e9–848.e16. 2020.PubMed/NCBI View Article : Google Scholar
34	Shin D, Ha S, O JH, Rhew SA, Yoon CE, Kwon HJ, Moon HW, Park YH, Park SY, Park C, et al: A single dose of novel PSMA-targeting radiopharmaceutical agent [¹⁷⁷Lu]ludotadipep for patients with metastatic castration-resistant prostate cancer: Phase i clinical trial. Cancers (Basel). 14(6225)2022.PubMed/NCBI View Article : Google Scholar
35	Jacoba IM and Weber HC: Biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Curr Opin Endocrinol Diabetes Obes. 30:175–180. 2023.PubMed/NCBI View Article : Google Scholar
36	Fernandes CJ, Leung G, Eads JR and Katona BW: Gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 51:625–647. 2022.PubMed/NCBI View Article : Google Scholar
37	Liu M, Wei L, Liu W, Chen S, Guan M, Zhang Y, Guo Z, Liu R and Xie P: Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016. Front Oncol. 13(1079575)2023.PubMed/NCBI View Article : Google Scholar
38	Harris PE and Zhernosekov K: The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front Endocrinol (Lausanne). 13(941832)2022.PubMed/NCBI View Article : Google Scholar
39	Theodoropoulou M and Stalla GK: Somatostatin receptors: From signaling to clinical practice. Front Neuroendocrinol. 34:228–252. 2013.PubMed/NCBI View Article : Google Scholar
40	Ichikawa Y, Kobayashi N, Takano S, Kato I, Endo K and Inoue T: Neuroendocrine tumor theranostics. Cancer Sci. 113:1930–1938. 2022.PubMed/NCBI View Article : Google Scholar
41	Pokuri VK, Fong MK and Iyer R: Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 18(7)2016.PubMed/NCBI View Article : Google Scholar
42	Das S, Al-Toubah T, El-Haddad G and Strosberg J: ¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 13:1023–1031. 2019.PubMed/NCBI View Article : Google Scholar
43	Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, et al: Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 376:125–135. 2017.PubMed/NCBI View Article : Google Scholar
44	Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, et al: ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22:1752–1763. 2021.PubMed/NCBI View Article : Google Scholar
45	Khan MS, Stamp E, Sammon C, Brabander T, de Herder WW and Pavel ME: Matching-adjusted indirect treatment comparison of [¹⁷⁷Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [¹⁷⁷Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. EJC Suppl. 16:5–13. 2021.PubMed/NCBI View Article : Google Scholar
46	Alsadik S, Gnanasegaran G, Chen L, Quigley AM, Mandair D, Toumpanakis C, Caplin M and Navalkissoor S: Safety and efficacy of 177 Lu-DOTATATE in neuroendocrine tumor patients with extensive bone disease. Clin Nucl Med. 48:667–672. 2023.PubMed/NCBI View Article : Google Scholar
47	Albrecht J, Exner S, Grötzinger C, Prasad S, Konietschke F, Beindorff N, Kühl AA, Prasad V, Brenner W and Koziolek EJ: Multimodal imaging of 2-cycle PRRT with ¹⁷⁷Lu-DOTA-JR11 and ¹⁷⁷Lu-DOTATOC in an orthotopic neuroendocrine xenograft tumor mouse model. J Nucl Med. 62:393–398. 2021.PubMed/NCBI View Article : Google Scholar
48	Mansi R, Plas P, Vauquelin G and Fani M: Distinct in vitro binding profile of the somatostatin receptor subtype 2 antagonist [¹⁷⁷Lu]Lu-OPS201 compared to the agonist [¹⁷⁷Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel). 14(1265)2021.PubMed/NCBI View Article : Google Scholar
49	Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, et al: Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 49:3651–3667. 2022.PubMed/NCBI View Article : Google Scholar
50	Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M, Ungewiss J, Haase C, et al: Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. 50:2621–2635. 2023.PubMed/NCBI View Article : Google Scholar
51	Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, et al: Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using ¹⁷⁷Lu-FAP-2286: First-in-humans results. J Nucl Med. 63:415–423. 2022.PubMed/NCBI View Article : Google Scholar
52	Minczeles NS, Bos EM, de Leeuw RC, Kros JM, Konijnenberg MW, Bromberg JEC, de Herder WW, Dirven CMF, Hofland J and Brabander T: Efficacy and safety of peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. Eur J Nucl Med Mol Imaging. 50:1195–1204. 2023.PubMed/NCBI View Article : Google Scholar
53	Nishida H, Kondo Y, Kusaba T, Kadowaki H and Daa T: Immunohistochemical reactivity of prostate-specific membrane antigen in salivary gland tumors. Head Neck Pathol. 16:427–433. 2022.PubMed/NCBI View Article : Google Scholar
54	van Boxtel W, Uijen MJM, Verhaegh GW, Willems SM and Jonker MA: PALGA Group. Schalken JA, van Engen-van Grunsven ICH and van Herpen CML: Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. Oral Oncol. 110(105018)2020.PubMed/NCBI View Article : Google Scholar
55	van Boxtel W, Lütje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, Nagarajah J, Gotthardt M and van Herpen CML: ⁶⁸Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: A phase 2 imaging study. Theranostics. 10:2273–2283. 2020.PubMed/NCBI View Article : Google Scholar
56	Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, et al: PSMA radioligand therapy for solid tumors other than prostate cancer: Background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 48:4350–4368. 2021.PubMed/NCBI View Article : Google Scholar
57	Lütje S, Sauerwein W, Lauenstein T, Bockisch A and Poeppel TD: In vivo visualization of prostate-specific membrane antigen in adenoid cystic carcinoma of the salivary gland. Clin Nucl Med. 41:476–477. 2016.PubMed/NCBI View Article : Google Scholar
58	Klein Nulent TJW, van Es RJJ, Willems SM, Braat AJAT, Devriese LA, de Bree R and de Keizer B: First experiences with ¹⁷⁷Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 11(126)2021.PubMed/NCBI View Article : Google Scholar
59	Terroir M, Lamesa C, Krim M, Vija L, Texier JS, Cassou-Mounat T, Delord JP, Vallot D and Courbon F: Radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-617 for salivary gland cancers: Literature review and first compassionate use in France. Pharmaceuticals (Basel). 16(754)2023.PubMed/NCBI View Article : Google Scholar
60	Lütje S, Gomez B, Cohnen J, Umutlu L, Gotthardt M, Poeppel TD, Bockisch A and Rosenbaum-Krumme S: Imaging of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-HBED-CC-PSMA PET/CT. Clin Nucl Med. 42:20–25. 2017.PubMed/NCBI View Article : Google Scholar
61	Lawhn-Heath C, Yom SS, Liu C, Villanueva-Meyer JE, Aslam M, Smith R, Narwal M, Juarez R, Behr SC, Pampaloni MH, et al: Gallium-68 prostate-specific membrane antigen ([⁶⁸Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: A feasibility study. EJNMMI Res. 10(128)2020.PubMed/NCBI View Article : Google Scholar
62	Sollini M, Kirienko M, di Tommaso L, Pini C, Gelardi F, Ariano S, Lania AG, Mazziotti G, Mercante G and Chiti A: The complementary role of PSMA expression and [¹⁸F]FDG PET/CT in predicting thyroid cancer outcome: From black and white to shades of gray, in the era of precision oncology. EJNMMI Res. 13(54)2023.PubMed/NCBI View Article : Google Scholar
63	Pitalua-Cortes Q, García-Perez FO, Vargas-Ahumada J, Gonzalez-Rueda S, Gomez-Argumosa E, Ignacio-Alvarez E, Soldevilla-Gallardo I and Torres-Agredo L: Head-to-head comparison of ⁶⁸Ga-PSMA-11 and 131I in the follow-up of well-differentiated metastatic thyroid cancer: A new potential theragnostic agent. Front Endocrinol (Lausanne). 12(794759)2021.PubMed/NCBI View Article : Google Scholar
64	Assadi M and Ahmadzadehfar H: 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment. World J Nucl Med. 18:406–408. 2019.PubMed/NCBI View Article : Google Scholar
65	de Vries LH, Lodewijk L, Braat AJAT, Krijger GC, Valk GD, Lam MGEH, Borel Rinkes IHM, Vriens MR and de Keizer B: ⁶⁸Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with ₁₇₇Lu-PSMA-617. EJNMMI Res. 10(18)2020.PubMed/NCBI View Article : Google Scholar
66	Pastoreková S, Parkkila S, Parkkila AK, Opavský R, Zelník V, Saarnio J and Pastorek J: Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 112:398–408. 1997.PubMed/NCBI View Article : Google Scholar
67	Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, Debruyne FM, Corstens FH and Oosterwijk E: Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res. 19:1197–1200. 1999.PubMed/NCBI
68	Stillebroer AB, Boerman OC, Desar IME, Boers-Sonderen MJ, van Herpen CML, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ and Mulders PF: Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 64:478–485. 2013.PubMed/NCBI View Article : Google Scholar
69	Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF, van Herpen CM, Langenhuijsen JF, Oosterwijk E, et al: Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 69:767–770. 2016.PubMed/NCBI View Article : Google Scholar
70	Elboga U, Kilbas B, Sahin E, Cayırlı YB, Eryilmaz K, Begec T, Bakar HE, Mercanoglu G and Celen YZ: An automated synthesis of 177Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical. Eur Rev Med Pharmacol Sci. 25:4829–4834. 2021.PubMed/NCBI View Article : Google Scholar
71	Askari E, Harsini S, Vahidfar N, Divband G and Sadeghi R: ¹⁷⁷Lu-EDTMP for metastatic bone pain palliation: A systematic review and meta-analysis. Cancer Biother Radiopharm. 36:383–390. 2021.PubMed/NCBI View Article : Google Scholar
72	Mercanoglu G, Zilbeyaz K and Arslan N: Synthesis and ready to use kit formulation of EDTMP for the preparation of 177Lu-EDTMP as a bone palliation radiopharmaceutical. Curr Radiopharm. 16:38–43. 2023.PubMed/NCBI View Article : Google Scholar
73	Chen H, Zhao L, Fu K, Lin Q, Wen X, Jacobson O, Sun L, Wu H, Zhang X, Guo Z, et al: Integrin α_vβ₃-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics. 9:7948–7960. 2019.PubMed/NCBI View Article : Google Scholar
74	Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G and Giaccone G: Phase I study of the ¹⁷⁷Lu-DOTA⁰-Tyr³-octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 8(e000980)2020.PubMed/NCBI View Article : Google Scholar